Policy
The $1.2 trillion budget package will now move to the Senate, which is expected to hold a vote next week.
FEATURED STORIES
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
Acadia Pharma’s Catherine Owen Adams is one of the founders of a group of small- to mid-cap biotechs advocating against a ‘peanut butter blanket’ approach to drug pricing for small companies.
Former European Trade Commissioner Phil Hogan and former US Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
This is an area where the U.S. is considering changes as well. Earlier this year, the U.S. Department of Health and Human Services proposed a new policy called the International Pricing Index.
Sareum Holdings PLC, the specialist small molecule drug development business notes that Sierra Oncology, the licence holder advancing clinical cancer candidate SRA737, has announced its financial and operational results for the second quarter 2019 ended 30 June 2019.
Esperion provided bempedoic acid franchise development program updates and financial results for the second quarter ended June 30, 2019.
Neos Therapeutics, Inc. reported financial results for the second quarter ended June 30, 2019 and provided a business update.
Researchers from Singapore and the United States are focused on a novel drug candidate with marine origins as a new method to prevent or treat vision loss.
Catalyst Pharmaceuticals, Inc. reported financial results for the second quarter ended June 30, 2019 and provided a corporate update.
Global Blood Therapeutics, Inc. reported recent business progress and financial results for the second quarter ended June 30, 2019.
Vericel Corporation reported financial results for the second quarter ended June 30, 2019, and recent business highlights.
MyoKardia, Inc. reported financial results for the second quarter ended June 30, 2019.
Biopharma companies working with the microbiome are running into patent obstacles due to the difficulty in using the system to protect naturally-occurring substances.